Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II study of gemcitabine (G), bevacizumab (B), and erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas

A phase II study of gemcitabine (G), bevacizumab (B), and erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas. Proc Am Soc Clin Oncology. 2008.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.